A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Moderate Alzheimer's Disease
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Tertomotide (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors KAEL-GemVax
Most Recent Events
- 15 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 May 2019 Status changed from planning to not yet recruiting.
- 14 May 2019 New trial record